Blumhagen, Rachel Z.
Kurche, Jonathan S.
Cool, Carlyne D.
Walts, Avram D.
Heinz, David
Fingerlin, Tasha E.
Yang, Ivana V.
Schwartz, David A.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01-HL097163, R01-HL148437, R01-HL158668, P01-HL092870, UH3- HL123442, UG3-HL151865)
VA Merit Review (IO1BX005295)
U.S. Department of Defense (W81XWH-17-1-0597)
Article History
Received: 10 July 2023
Accepted: 21 October 2023
First Online: 17 November 2023
Declarations
:
: Dr. Blumhagen is supported by sponsored research agreement from Eleven P15, Inc., outside the submitted work. Dr. Schwartz is the founder and unpaid chief scientific officer of Eleven P15, Inc., and serves as a consultant for Vertex Pharmaceuticals. Dr. Fingerlin and Dr. Yang report consulting fees from Eleven P15, Inc., outside the submitted work and Drs. Schwartz, Fingerlin, and Yang have a patent Methods and Compositions for Risk Prediction, Diagnosis, Prognosis, and Treatment of Pulmonary Disorders issued. Dr. Cool reports consultant fees from Eleven P15, Inc. and Theralink Technologies. Dr. Kurche, Avram Walts, and David Heinz report no competing interests.
: De-identified data and samples were approved for use in this study by the Colorado Multiple Institutional Review Board (COMIRB #15-1147). Patients were consented and tissue was collected through the NHLBI-sponsored Lung Tissue Research Consortium (LTRC) and at the University of Colorado.